This week, Genomeweb reported that UBS (which in part issues investment advisories) had downgraded Illumina's stock rating (here). The major recent activity at ILMN was buying Grail, a well-funded company advancing tests for cancer detection.
Today, at the Cowen Liquid Biopsy investment summit, Exact Sciences includes a slide that while 166 people need to be screened to detect just 1 colon cancer, a Multi Cancer liquid biopsy test could potentially be able to detect a cancer while screened only 30 people (19 page deck here). I haven't heard the whole talk yet but it has a link on the Exact website here. Cowen's next slide releases product-specific data.
Stock Shot Upward - Billions in Market Cap
Exact stock shot up by what CNBC is currently rating at 24%. Since the market cap has been about $10B , that's about $2B-3B in stock market value.
The five-day performance from Yahoo Finance is here: